LONG BEACH, CA, May 07, 2018 (GLOBE NEWSWIRE) -- Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today the appointments of Douglas Cesario, MBA, as its Chief Financial Officer and Wendy Cunning as its Vice President of Business Operations. Elizabeth Berecz, MA, CPA, has resigned from her role as Chief Financial Officer effective May 25, 2018.
"I am excited to welcome transformational leaders like Doug and Wendy to Nemus,” said Dr. Brian Murphy, Chief Executive Officer and Chief Medical Officer of Nemus. “Adding executives of their caliber and experience will provide immense value to Nemus as we continue to expand our drug discovery and development activities across a spectrum of diseases with our proprietary, bio-engineered cannabinoid-based therapeutics.”
Dr. Murphy continued, "We thank Elizabeth Berecz, who has served as Chief Financial Officer since July 1, 2014. We deeply appreciate her dedication and valuable contributions to Nemus' growth."
Mr. Cesario brings over 15 years of financial and operational experience across many industries. Prior to joining Nemus, Mr. Cesario served as Chief Financial Officer of Kaiser Permanente Foundation Hospitals and Health Plan in the Orange County, California marketplace, where he managed the financial performance of the health system with an operating budget of over $1 billion per year. Previously Mr. Cesario held various financial leadership positions, including founder of Community Capital Advisory Group, a real estate advisory and investment company; director of Skye Automotive, a private equity fund; and corporate finance associate at both full service and boutique investment banking firms. Mr. Cesario earned a Master’s in Business Administration from the UCLA Anderson School of Management.
Ms. Cunning brings over 20 years of extensive expertise in U.S. sales, marketing, global new product development, commercialization, and lifecycle management in the biopharmaceutical industry. Prior to joining Nemus, Ms. Cunning served as Director, New Products, U.S. Eye Care at Allergan, where she led the creation of the business unit strategy for the U.S. ocular franchise. She was the Associate Director of Marketing at Amylin Pharmaceuticals, leading the global life-cycle management for Byetta®. Additionally, she held leadership positions at Valeant Pharmaceuticals, a multi-billion dollar pharmaceutical company, as the global marketing and commercial development lead for both the viral hepatitis and HIV franchises. Prior to joining Valeant, Ms. Cunning worked in Hepsera® marketing at Gilead Sciences and sales in HIV and respiratory medicine at GlaxoSmithKline. Ms. Cunning earned a bachelor's degree in biology from West Virginia University.
ABOUT NEMUS BIOSCIENCE, INC.
The Company is a biopharmaceutical company, headquartered in Long Beach, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, NEMUS is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. NEMUS's strategy is to explore the use of proprietary biosynthetic compounds, alone or in combination with corporate partners. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.
For more information, visit www.nemusbioscience.com.
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, including statements regarding our product development and business strategy. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “contemplates,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Nemus may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Nemus’ most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Nemus disclaims any intent or obligation to update these forward-looking statements.
This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any securities that may be offered in the United States will be offered only to accredited investors pursuant to Regulation D of the Securities Act.
CONTACT: CONTACT: NEMUS Investor Relations PCG Advisory Group Adam Holdsworth Email: firstname.lastname@example.org Phone: 646-862-4607